Literature DB >> 14986161

Granulocyte colony-stimulating factor and an in vitro whole blood model of melioidosis.

A C Cheng1, P Dasari, B J Currie.   

Abstract

The study reported here was conducted in order to explore the mechanism of action of granulocyte colony-stimulating factor (G-CSF) in the treatment of Burkholderia pseudomallei infections (otherwise known as melioidosis). Use of G-CSF as an adjunct to antibiotics has been associated with decreasing mortality among patients with melioidosis in the tropical region of the Northern Territory of Australia. However, using an in vitro whole blood assay, no significant difference was detected in the bactericidal activity of samples obtained from dialysis patients, patients with type 2 diabetes mellitus and healthy controls, and there was no improvement following coincubation with G-CSF.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14986161     DOI: 10.1007/s10096-003-1088-y

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  14 in total

1.  Interaction of insulin with Burkholderia pseudomallei may be caused by a preservative.

Authors:  A J Simpson; V Wuthiekanun
Journal:  J Clin Pathol       Date:  2000-02       Impact factor: 3.411

2.  A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. CAP Study Group.

Authors:  S Nelson; S M Belknap; R W Carlson; D Dale; B DeBoisblanc; S Farkas; N Fotheringham; H Ho; T Marrie; H Movahhed; R Root; J Wilson
Journal:  J Infect Dis       Date:  1998-10       Impact factor: 5.226

Review 3.  Granulocyte colony-stimulating factor to prevent the progression of systemic nonresponsiveness in systemic inflammatory response syndrome and sepsis.

Authors:  M Weiss; L L Moldawer; E M Schneider
Journal:  Blood       Date:  1999-01-15       Impact factor: 22.113

4.  A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumonia.

Authors:  S Nelson; A M Heyder; J Stone; M G Bergeron; S Daugherty; G Peterson; N Fotheringham; W Welch; S Milwee; R Root
Journal:  J Infect Dis       Date:  2000-08-17       Impact factor: 5.226

5.  Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils.

Authors:  E Roilides; T J Walsh; P A Pizzo; M Rubin
Journal:  J Infect Dis       Date:  1991-03       Impact factor: 5.226

6.  Burkholderia pseudomallei activates complement and is ingested but not killed by polymorphonuclear leukocytes.

Authors:  A M Egan; D L Gordon
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

7.  Intracellular survival of Burkholderia pseudomallei.

Authors:  A L Jones; T J Beveridge; D E Woods
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

8.  Survival of Vibrio vulnificus in whole blood from patients with chronic liver diseases: association with phagocytosis by neutrophils and serum ferritin levels.

Authors:  L I Hor; T T Chang; S T Wang
Journal:  J Infect Dis       Date:  1999-01       Impact factor: 5.226

9.  Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis.

Authors:  Allen C Cheng; Dianne P Stephens; Nicholas M Anstey; Bart J Currie
Journal:  Clin Infect Dis       Date:  2003-12-04       Impact factor: 9.079

10.  Survival of Pseudomonas pseudomallei in human phagocytes.

Authors:  S Pruksachartvuthi; N Aswapokee; K Thankerngpol
Journal:  J Med Microbiol       Date:  1990-02       Impact factor: 2.472

View more
  5 in total

1.  Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.

Authors:  Katie L Propst; Ryan M Troyer; Lisa M Kellihan; Herbert P Schweizer; Steven W Dow
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

Review 2.  Human Melioidosis.

Authors:  I Gassiep; M Armstrong; R Norton
Journal:  Clin Microbiol Rev       Date:  2020-03-11       Impact factor: 26.132

3.  Human polymorphonuclear neutrophil responses to Burkholderia pseudomallei in healthy and diabetic subjects.

Authors:  Sujin Chanchamroen; Chidchamai Kewcharoenwong; Wattanachai Susaengrat; Manabu Ato; Ganjana Lertmemongkolchai
Journal:  Infect Immun       Date:  2008-10-27       Impact factor: 3.441

4.  Polysaccharide specific monoclonal antibodies provide passive protection against intranasal challenge with Burkholderia pseudomallei.

Authors:  David P AuCoin; Dana E Reed; Nicole L Marlenee; Richard A Bowen; Peter Thorkildson; Barbara M Judy; Alfredo G Torres; Thomas R Kozel
Journal:  PLoS One       Date:  2012-04-17       Impact factor: 3.240

5.  Capsule influences the deposition of critical complement C3 levels required for the killing of Burkholderia pseudomallei via NADPH-oxidase induction by human neutrophils.

Authors:  Michael E Woodman; Randall G Worth; R Mark Wooten
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.